Very long-chain saturated fatty acids in plasma lipids: association with cardiometabolic risk influenced by lipid interactions
Authors' conclusion
VLCSFA show different metabolic roles in cardiometabolic diseases and highlight the importance of adjusting for confounding by correlated lipids. These findings challenge the traditional view that SFA exert uniform negative effects and suggest class-specific VLCSFA profiles may improve risk prediction of cardiometabolic diseases, guiding more precise prevention strategies.
Study context
- Population
- EPIC-Potsdam cohort; T2D case-cohort 1911 (774 cases), cardiovascular disease (CVD) case-cohort 1704 (547 cases)two case-cohorts
- Exposure
- Plasma very long-chain saturated fatty acids (VLCSFA) (C20:0, C22:0, C24:0) across 12 lipid classes, per SD, adjusted for correlated lipids
- Outcome
- Incident T2D and CVD
Methodological detailstwo nested case-cohort studies, prospective, EPIC-Potsdam cohort, data-driven lipid network, multivariable-adjusted Cox regression
- Two nested case-cohort studies
- Prospective
- EPIC-Potsdam cohort
- Data-driven lipid network
- Multivariable-adjusted Cox regression
Main finding
As reported in the abstract
Ceramide C20:0, HR per SD
0.52 (0.35-0.79) (95% CI)
Ceramide C24:0, HR per SD
0.46 (0.27-0.79) (95% CI)
Dihydroceramide C20:0, HR per SD
1.36 (1.07-1.72) (95% CI)
Sphingomyelin C24:0, HR per SD
1.61 (1.15-2.26) (95% CI)
Observational data: associations, not effects.
Further findings
Distribution of VLCSFA across lipid classes
- C20:0 distributed across more lipid classes than C22:0 and C24:0
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →